Study guide
Antiplatelet Management & Platelet Dysfunction
ABPN Neurocritical Care Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU
Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU
2 Chapter 2: Cerebral Physiology & Intracranial Dynamics
Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes
3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management
Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions
4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management
Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy
5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management
Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury
6 Chapter 6: Neuropharmacology, Analgesia & Sedation
ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU
7 Bleeding, Thrombosis & Hematologic Emergencies
Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity
8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine
Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention
9 Systemic Trauma & Environmental Injury
Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging
10 Cardiac Emergencies & Mechanical Support
IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies
11 Kidney Injury, Acid–Base & Renal Replacement
Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement
12 Systemic Infection & Endocrine Emergencies
Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies
13 Gastrointestinal & Hepatic Emergencies
Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects
14 Chapter 9: Neuroimaging in the Neuro-ICU
Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness
15 Chapter 10: Electrophysiology & Neuromonitoring
Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler
16 Angiography, Electrodiagnosis & CSF Analysis
Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage
17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria
Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria
18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies
Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction
19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage
Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH
20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia
Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations
21 Venous, Spinal & Traumatic Vascular Disease
Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury
22 Chapter 15: Traumatic Brain & Spinal Cord Injury
Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes
23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies
Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure
24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis
Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies
25 Neuroinflammation & Neurooncology
Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies
26 Pregnancy, Transplantation & Pediatric Care
Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care
27 Chapter 18: Neurosurgical & Perioperative Emergencies
Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies
28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU
Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor
Antiplatelet Management & Platelet Dysfunction
Key Takeaways Explain This Topic AI
PATCH found worse functional outcomes with platelet transfusion in its selected nonsurgical spontaneous-ICH population, predominantly exposed to aspirin.
AHA/ASA recommends against platelet transfusion in aspirin-associated spontaneous ICH without emergency surgery; procedural and quantitative platelet problems require separate assessment.
DDAVP can be considered under some protocols, but effectiveness for antiplatelet-associated ICH is uncertain and hyponatremia is a concern.
A platelet-function assay result is not by itself a reason to transfuse a nonsurgical ICH patient.
Last updated: October 2026
Antiplatelet Management & Platelet Dysfunction
Antiplatelet agents are widely prescribed for primary and secondary cardiovascular and cerebrovascular prevention. When patients taking antiplatelet medications suffer acute intracranial hemorrhage ( I C H ICH I C H ), clinicians confront an intricate hemostatic challenge. Historically, clinical intuition led physicians to transfuse donor platelets empirically to "reverse" the drug effect. However, high-level randomized clinical trial evidence has dismantled this historical dogma, transforming platelet transfusion from a routine standard of care into a proven source of patient harm.
Antiplatelet Agents & Mechanisms of Action
Platelets play a foundational role in primary hemostasis by adhering to damaged endothelium, undergoing shape change and granule secretion, and aggregating via activated glycoprotein I I b / I I I a IIb/IIIa II b / III a ( G P I I b / I I I a GPIIb/IIIa GP II b / III a ) receptors to form a primary hemostatic plug. Antiplatelet Pharmacological Targets
Cyclooxygenase-1 (COX-1) Pathway:
Aspirin ── Irreversible acetylation of Ser-529 ── Blocks Thromboxane A2 (TXA2)
Purinergic P2Y12 ADP Receptor Pathway:
- Clopidogrel & Prasugrel ── Hepatic CYP activation ── Irreversible P2Y12 covalent binding
- Ticagrelor ────────────── Direct-acting ────────────── Reversible P2Y12 allosteric inhibition
- Cyclooxygenase-1 Inhibitors (Aspirin)
Aspirin irreversibly acetylates the serine 529 residue of cyclooxygenase-1 ( C O X − 1 COX-1 COX − 1 ), permanently blocking the conversion of arachidonic acid to prostaglandin H 2 H_2 H 2 and subsequent synthesis of thromboxane A 2 A_2 A 2 ( T X A 2 TXA_2 TX A 2 ) . Because anucleate platelets cannot synthesize new proteins, C O X − 1 COX-1 COX − 1 remains inhibited for the entire lifespan of the circulating platelet ( 7 to 10 days 7\text{ to }10\text{ days} 7 to 10 days ). Approximately 10 % 10\% 10% of circulating platelets are renewed daily via bone marrow thrombopoiesis, restoring baseline hemostatic competence within 3 to 5 days 3\text{ to }5\text{ days} 3 to 5 days following drug cessation.
Purinergic P2Y12 Receptor Antagonists
Thienopyridines (Clopidogrel & Prasugrel): Prodrugs requiring hepatic cytochrome P450 bioactivation ( C Y P 2 C 19 CYP2C19 C Y P 2 C 19 for clopidogrel; C Y P 3 A 4 / 2 B 6 CYP3A4/2B6 C Y P 3 A 4/2 B 6 for prasugrel). The active thiol metabolite forms a disulfide bond that covalently and irreversibly inactivates the platelet P 2 Y 12 P2Y_{12} P 2 Y 12 adenosine diphosphate ( A D P ADP A D P ) receptor. Inactivation prevents G i G_i G i -protein mediated adenylyl cyclase inhibition, suppressing inside-out signaling required to activate G P I I b / I I I a GPIIb/IIIa GP II b / III a receptors.
Non-Thienopyridine (Ticagrelor): A cyclopentyltriazolopyrimidine that functions as a direct-acting, chemically reversible , non-competitive allosteric antagonist of the P 2 Y 12 P2Y_{12} P 2 Y 12 receptor. It does not require hepatic metabolic activation and exhibits an elimination half-life of 7 to 12 hours 7\text{ to }12\text{ hours} 7 to 12 hours .
The Landmark PATCH Trial: Evidence-Based Harm
For decades, neurosurgeons and neurointensivists routinely administered 1 to 2 units of donor platelets to any patient with acute I C H ICH I C H who had taken aspirin or clopidogrel. The multi-center, open-label, randomized controlled PATCH trial ( Platelet Transfusion in Cerebral Haemorrhage , published in The Lancet , 2016) directly tested this paradigm in 190 patients with spontaneous primary I C H ICH I C H who presented within 6 hours of symptom onset after taking antiplatelet agents within the previous 7 days.
Key Findings of the PATCH Trial
Increased Disability and Death: Patients randomly allocated to receive platelet transfusion had significantly higher odds of death or severe functional dependence (modified Rankin Scale m R S 4 to 6 mRS\text{ }4\text{ to }6 m RS 4 to 6 ) at 3 months compared to those receiving standard non-transfusional care ( adjusted common odds ratio 2.05 2.05 2.05 , 95 % 95\% 95% CI 1.18 – 3.56 1.18\text{--}3.56 1.18 – 3.56 , p = 0.0114 p = 0.0114 p = 0.0114 ).
Excess Mortality: In-hospital mortality was markedly higher in the platelet transfusion arm ( 24 % 24\% 24% vs. 17 % 17\% 17% ).
Excess Serious Adverse Events: Serious complications occurred in 42 % 42\% 42% of platelet-transfused patients versus 29 % 29\% 29% in the control cohort.
Why the Trial Does Not Answer Every Transfusion Question
PATCH did not study every procedural, traumatic, thrombocytopenic, or drug-specific situation. Circulating ticagrelor can inhibit transfused platelets, but aspirin and clopidogrel pharmacokinetics are different. Do not assume that all donor platelets are immediately rendered useless by every antiplatelet exposure. Clinical applicability follows the studied population and the actual indication.
Current Guideline Recommendations & Surgical Exceptions
The 2022 American Heart Association / American Stroke Association ( A H A / A S A AHA/ASA A H A / A S A ) Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage codified the findings of the PATCH trial into strict clinical recommendations:
Warning
AHA/ASA Guideline Recommendation (Class III: Harm, Level of Evidence B-R): In patients with acute spontaneous non-surgical intracerebral hemorrhage who were taking antiplatelet therapy prior to ictus, platelet transfusions are CONTRAINDICATED because they increase mortality and severe disability.
Surgical and Quantitative Platelet Problems
For aspirin-treated spontaneous ICH requiring emergency neurosurgery, AHA/ASA states that platelets might be considered to reduce postoperative bleeding and mortality. The evidence should not be generalized into a mandatory transfusion rule for every EVD or every P2Y12 inhibitor. True thrombocytopenia, active bleeding, and a specific procedure require separate hematology and procedural assessment. Conventional neurosurgical targets do not establish a universal threshold for all nonsurgical ICH.
Role of Desmopressin (DDAVP)
Desmopressin ( 1 -deamino-8- D -arginine vasopressin 1\text{-deamino-8-}D\text{-arginine vasopressin} 1 -deamino-8- D -arginine vasopressin , D D A V P DDAVP DD A V P ) is a proposed hemostatic adjunct whose clinical effectiveness in antiplatelet-associated ICH remains uncertain and which has important adverse effects for augmenting platelet hemostasis in antiplatelet-exposed or uremic neuro-ICU patients.
Mechanism of Action
DDAVP is a synthetic structural analog of arginine vasopressin that selectively binds endothelial vasopressin V 2 V_2 V 2 receptors . Activation of V 2 V_2 V 2 receptors stimulates adenylyl cyclase, raising intracellular c A M P cAMP c A MP and triggering immediate exocytosis of endothelial storage granules ( Weibel-Palade bodies ). This exocytosis releases large multimers of von Willebrand factor ( v W F vWF v W F ) and Factor VIII into plasma, increasing circulating v W F vWF v W F levels by 2 to 4 -fold 2\text{ to }4\text{-fold} 2 to 4 -fold . DDAVP → V 2 Receptors Weibel-Palade Exocytosis → ↑ Endothelial vWF + ↑ Factor VIII → ↑ Platelet Adhesion (GPIb-IX-V) \text{DDAVP} \xrightarrow{V_2\text{ Receptors}} \text{Weibel-Palade Exocytosis} \xrightarrow{} \uparrow\text{ Endothelial vWF } + \uparrow\text{ Factor VIII} \xrightarrow{} \uparrow\text{ Platelet Adhesion (GPIb-IX-V)} DDAVP V 2 Receptors Weibel-Palade Exocytosis ↑ Endothelial vWF + ↑ Factor VIII ↑ Platelet Adhesion (GPIb-IX-V)
Elevated v W F vWF v W F binds subendothelial collagen and platelet glycoprotein I b − I X − V Ib-IX-V I b − I X − V complexes, enhancing shear-stress platelet adhesion and mechanical bridging, potentially improving platelet adhesion without directly reversing COX-1 or P2Y12 receptor blockade.
Dosing Protocol & Hyponatremia Risk
Dose & Route: 0.4 μ g/kg 0.4\text{ }\mu\text{g/kg} 0.4 μ g/kg IV (diluted in 50 mL 50\text{ mL} 50 mL normal saline, infused over 30 minutes 30\text{ minutes} 30 minutes ; maximum according to the institutional protocol).
Onset & Tachyphylaxis: Onset occurs within 30 minutes 30\text{ minutes} 30 minutes and persists for 4 to 6 hours 4\text{ to }6\text{ hours} 4 to 6 hours . Repeat dosing within 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours exhibits marked tachyphylaxis due to exhaustion of endothelial Weibel-Palade stores.
Hyponatremia Hazard: As a V 2 V_2 V 2 agonist, DDAVP exerts potent antidiuretic properties, causing renal free-water retention. In neurocritical care, acute hyponatremia exacerbates cerebral edema and intracranial pressure. Clinicians must institute strict free-water restriction and monitor serum sodium every 6 hours 6\text{ hours} 6 hours for 24 hours 24\text{ hours} 24 hours following administration.
- Clinical Characteristic Platelet Transfusion Desmopressin (DDAVP)
- Mechanism Exogenous donor platelet infusion Endothelial release of endogenous vWF and Factor VIII
Non-Surgical ICH Indication Class III: Harm (Strictly Contraindicated) Effectiveness uncertain in antiplatelet-associated ICH
Surgical Indication Emergent craniotomy / EVD with antiplatelet exposure Adjunct prior to neurosurgical instrumentation
Mortality Impact (PATCH) Significantly increased death/disability (OR 2.05) No evidence of increased mortality
Primary Adverse Risk Microvascular thrombosis, penumbral infarction Hyponatremia , free-water retention, tachyphylaxis
Platelet Function Testing & Viscoelastic Assays
Point-of-care platelet function analyzers quantify the pharmacodynamic inhibition of platelets:
VerifyNow P2Y12 Assay: Optical turbidimetric aggregometry reporting P 2 Y 12 P2Y_{12} P 2 Y 12 Reaction Units ( P R U PRU PR U ) . Baseline uninhibited value is typically > 200 PRU > 200\text{ PRU} > 200 PRU . Therapeutic clopidogrel or ticagrelor inhibition is reflected by P R U < 180 to 208 PRU < 180\text{ to }208 PR U < 180 to 208 .
VerifyNow Aspirin Assay: Measures arachidonic acid-induced aggregation in Aspirin Reaction Units ( A R U ARU A R U ) . Normal uninhibited function is ≥ 550 ARU \ge 550\text{ ARU} ≥ 550 ARU ; therapeutic aspirin effect is < 550 ARU < 550\text{ ARU} < 550 ARU .
TEG PlateletMapping: Evaluates maximum clot strength ( M A MA M A ) generated via thrombin versus arachidonic acid ( M A A A MA_{AA} M A AA ) or adenosine diphosphate ( M A A D P MA_{ADP} M A A D P ), reporting percent platelet inhibition.
Note
Diagnostic Role vs. Transfusion Trap: Platelet function testing documents medication adherence and confirms receptor blockade. However, multiple prospective studies have demonstrated that administering platelet transfusions to "correct" a low PRU or ARU in non-surgical patients does not improve outcomes and replicates PATCH-like harm . Management decisions must adhere to clinical trials rather than pursuing in vitro laboratory normalization.